Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

Read more breaking news



People on the move; outsourcing jobs

By Natalie Morrison , 02-Jan-2012

Outsourcing-Pharma presents its first round-up of the movers and shakers within the pharmaceutical industry of 2012, including news from Icon, Marken and ClinStar.

Anthony Murphy has announced his retirement from the role of non-executive director at Icon.


Murphy joined the board for the Irish-based CRO (contract research organisation) in April 2009, shortly before he retired as senior VP of human resources for Eli Lilly in the May.


Of his departure, Icon chairman Bruce Given said: "I would like to express the Board's thanks and appreciation for Tony's advice and support during his time on the Board and to convey the Board's best wishes to him for the future.”


Cambrex VP of sales and business development for North America, Eric Neuffer, has been drafted into the Society of Chemical Manufacturers and Affiliates’ (SOCMA) 2014 board of governors class.


Neuffer – an employee at small molecule services company Cambrex since 1999 – will serve a three-year term for the trade association.


He has been active with SOCMA since 2007 serving on the SOCMA commercial services committee, the membership committee and the informex committee.


In 2011, Neuffer also served on the organisation’s sales and marketing peer group advisory panel.


“I am honored to be elected to the Board of Governors and over the next three years, I look forward to working with my fellow board colleagues to promote SOCMA’s services for the chemical industry,” he said.


Marken has named Steve Roese as VP of its global quality assurance organisation.


Roese joins the clinical supply chain services firm after 30 years in quality operations at Wyeth Pharmaceuticals (now Pfizer).


The company says Roese’s appointment will help support its continued investment the expanding network of pharmaceutical service depots in Europe, Asia and the US.


Wes Wheeler, CEO of Marken, said: "Given our emphasis on clinical storage and distribution of drug products, Steve's responsibilities will be a critically important priority for us.


“Quality has been, and will remain, a key part of our strategy in the future, and Steve's experience in the pharma industry will enable us to take quality to a whole new level."


IntegraGen has hired Laurence Riot Lamotte as Chief Financial Officer.


Prior to joining the firm, she was CFO of Aureus Sciences, a software publisher in the field of pharmaceutical research, as well as LBMA (Laboratoire de Biotechnologies Marines Appliquées), where she gained substantial experience of the health sector.


She will now help lead European and US expansion plans for the service provider, which specialises in the development and commercialisation of testing in the fields of Autism and Oncology.


Scottish gamma scintigraphy imaging provider Bio-Images Research has added Sarah Connolly to its board of directors.


Connolly, who has been with the Glasgow-based company for the past four years, will take responsibility for good manufacturing practice (GMP) as well as regulatory and ethics approvals.

Howard Stevens, founder of Bio-Images, said: "Dr Connolly has demonstrated a whole-hearted commitment to best practice in clinical study work and a deep understanding of the fundamentals of Good Manufacturing Practice. Her expertise will be invaluable as Bio-Images gears up for the next stages of international expansion."